Publications
363 publications
- Date
- Relevance
-
GVS advice setmelanotide (Imcivree®)
The National Health Care Institute advises the Minister to include setmelanotide (Imcivree®) in List 1B of the GVS. Setmelanotide ...
-
Position of the National Health Care Institute on nivolumab (Opdivo®) for the treatment of dMMR- of MSI tumors
The National Health Care Institute concludes that nivolumab (Opdivo®) for the treatment of certain patients with locally advanced ...
-
GVS advice elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in combination with ivacaftor (Kalydeco®): extension of further conditions
The National Health Care Institute advises the Minister to include cenobamate (Ontozry®) in List 1A of the GVS. Cenobamate is ...
-
International strategic agenda 2022-2023 National Health Care Institute
The international strategic agenda 2022-2023 describes the international activities of the National Health Care Institute ...
-
GVS advice liraglutide (Saxenda®), extension of further conditions for certain people with an extremely increased weight-related health risk
The National Health Care Institute advises the Minister to extend the List 2 conditions for liraglutide (Saxenda®). The ...
-
GVS advice vericiguat (Verquvo®) for the treatment of symptomatic chronic heart failure
The National Health Care Institute advises the Minister not to include vericiguat (Verquvo®) in the Medicine Reimbursement System ...
-
GVS advice on cenobamate (Ontozry®) for the adjunctive treatment of focal-onset seizures
The National Health Care Institute advises the Minister to include cenobamate (Ontozry®) in List 1A of the GVS. Cenobamate is ...
-
GVS advice ofatumumab (Kesimpta®) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS)
The National Health Care Institute advises the Minister to include ofatumumab (Kesimpta®) on List 1B of the GVS. Ofatumumab is ...
-
Package advice tisagenlecleucel (Kymriah®) for the treatment of r/r DLBCL
The National Health Care Institute has completed its reassessment whether tisagenlecleucel (Kymriah®) can be included in the ...
-
Package advice tucatinib (Tukysa®)
The National Health Care Institute has completed its assessment whether tucatinib (Tukysa®) in combination with trastuzumab and ...